News | April 08, 2013

Best Medical Expands Radiation Therapy Offers With New Acquisitions

 Best Medical Expansion Radiation Therapy Acquisitions

 

April 8, 2013 — TeamBest companies are planning for a major expansion by diversifying its area of expertise and product lines, to meet the growing demands of an increasing and aging population. Earlier this year, Best Medical International (BMI) purchased Envisioneering Medical Technologies’ assets including TargetScan Touch, an ultrasound based stereotactic biopsy guidance and tumor localization system. TargetScan data can be used to generate a predictive model of tumor locations and provide for micro-invasive curative techniques using EBRT (external beam radiation therapy) or brachytherapy or combination. Because of its ability to target and record biopsy locations the TargetScan Touch can provide for prostate cancer management protocols such as active surveillance and focal therapy. The acquisition of Envisioneering’s assets is part of TeamBest’s commitment to offer "Total Solutions for the Treatment of Prostate Cancer." This enhances the BMI portfolio of brachytherapy products, such as gold, iodine, iridium and palladium seeds and accessories for accurate diagnosis, treatment planning and treatment for the best possible clinical outcome. BMI now is the only company in the world providing these complete and comprehensive solutions for prostate cancer diagnosis and treatment.

One of the TeamBest companies, Best NOMOS, invented the technology known as IMRT (intensity modulated radiation therapy), and it is the global standard for treating cancer patients. Best NOMOS continues to invest millions of dollars annually to expand and upgrade these and other technologies to be in the forefront of cancer diagnosis and treatment.

Recently, the U.S. Food & Drug Administration (FDA) has provided marketing approval for Best Iodine seeds for breast tumor localization for more accurate cancer diagnosis and treatment. With a continued emphasis on Best Total Solutions, TeamBest will offer a complete range of products for comprehensive cancer management, from brachytherapy, external beam teletherapy, and proton to carbon, particle therapy. Presently TeamBest companies are bidding on projects worth $500 million or more, globally.

Best Vascular, another TeamBest company, manufactures the Novoste Beta-Cath System, an intravascular brachytherapy device used by cardiologists to treat in-stent restenosis in coronary arteries. Best Vascular is the only company in the world providing this unique life saving technology and it continues to pursue clinical research and trials for other indications.

Best Cure Foundation was established in 2007 to make quality healthcare and education affordable and accessible globally. The CURE Institute of Health Physics, a division of Best Cure Foundation, a non-profit organization, has been established to help train and assist those providing services in Medical and Non-medical (Industrial) enterprises.

TeamBest continues to provide Best Fellowships to residents and other medical professionals to attend medical conferences and workshops in their area of expertise.

TeamBest recently formed another new company, Best Dosimetry Services, to provide personnel dosimetry services for medical and non-medical workers handling hazardous materials.

One of TeamBest's new companies is Best NDT (Non Destructive Testing), which offers a wide range of products globally for the oil and gas pipeline industry such as isotopes, pipe crawlers, cameras and other devices and accessories, including quality assurance and quality control products.

USA and Canada alone will spend nearly $10 to $15 billion per month over the next two decades in oil and gas exploration, infrastructure, production and distribution. Kitsault Energy, established in 2013, is planning for a dedicated energy corridor/natural gas pipeline from North East British Columbia (Canada), Fort Nelson to Kitsault Resort (one of TeamBest companies), Energy Export Terminal and LNG (Liquefied Natural Gas) Facility at Kitsault, BC Canada. This is a multi phase program, spanning 8 to 10 years. The first phase is expected to cost $5 billion, the second phase $5 billion, third phase $10 billion, and the fourth phase will be approximately $10 to $15 billion.

The Best Global Talent Agency was established recently to meet the growing need of various industries for a highly trained and skilled labor force, and to provide training to Aboriginal First Nations Communities and others for these high paying jobs.

There are other expansion plans, all of which require huge investments and the need for highly trained and skilled staff. TeamBest has grown from a few employees to more than 500 employees with several offices in the United States, Canada, Europe and India and continue to add more new staff every month. TeamBest is investing $10 million or more every year in new product development, clinical research and trials. TeamBest plans to continue this for quite some time to expand the product portfolio globally.

For more information: www.teambest.com

 

Related Content

A new hybrid X-ray detector developed by the University of Surrey outperforms commercial devices — and could lead to more accurate cancer therapy.
News | X-Ray | December 03, 2020
December 3, 2020 — A new hybrid X-ray detector deve
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
December 2, 2020 — ...
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

News | Radiation Therapy | November 02, 2020
November 2, 2020 — A nonsurgical treatment option for...
Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

News | Ultrasound Imaging | November 02, 2020
November 2, 2020 — Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the
Updated results of NRG Oncology trial display effectiveness of gemcitabine and daily radiation for bladder preservation in muscle-invasive bladder cancer patients
News | Radiation Oncology | November 02, 2020
November 2, 2020 — Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectom
Follow up results on first multicenter trial to report outcomes of salvage low dose radiotherapy brachytherapy after external beam radiotherapy for prostate cancer
News | Prostate Cancer | October 30, 2020
October 30, 2020 — Researchers involved in the...